Stunning performance
During the third quarter of the year, sales grew by 9.3% to EGP5.725bn vs. EGP5.236bn, a year ago. The tobacco monopoly’s profits stood at EGP1.08bn, up by 28.3%, yoy. The EBITDA margin was up by 20 bp to 28%. Also, the net margin reached 18.86% by the end of March 2016 vs. 16.07% a year ago.EastPharma is a pharmaceutical company. Co. is engaged in the manufacture and marketing of branded and in-licensed generic pharmaceuticals in Turkey and other regional markets. Through its subsidiaries, Co. is engaged in the production and marketing of human pharmaceuticals, active pharmaceutical ingredients ("APIs") and veterinary products.
AlphaMena is the MENA stocks leader in independent equity research, covering 142. MENA securities spanning across 19 sectors and 8 countries relaying on a team of 11 analysts. The breadth of coverage allows AlphaMena to formulate a coherent view on markets, sectors and to highlight the best investments in Mena zone using a robust homogeneous and transparent methodology, enabling pure and pertinent comparisons based on financial and extra-financial criteria.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.